<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656759</url>
  </required_header>
  <id_info>
    <org_study_id>12032202-IRB01</org_study_id>
    <nct_id>NCT01656759</nct_id>
  </id_info>
  <brief_title>Use of a Novel Fibrin Sealant in Total Knee Arthroplasty</brief_title>
  <official_title>Use of a Novel Fibrin Sealant in Total Knee Arthroplasty: A Prospective Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Applying a fibrin spray, after knee device implantation, will help in reducing patient blood
      loss and decrease the drop in both hemoglobin and hematocrit levels. Also, with decreased
      blood loss there should be a reduced need for blood transfusions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design

      Study design and control methods:

      This study is designed as a prospective, randomized, double-blinded controlled clinical trial
      to compare the effect of a fibrin spray applied to the surgical wound as compared to patients
      not receiving the fibrin spray.

      Treatment group:

      The subjects will be randomly assigned to the fibrin treatment group or to the control group
      at the time of the surgery via the opening of a randomly selected sealed envelope. The
      patient and the independent reviewer will be blinded as to which treatment group the patient
      is assigned to. This information will be linked to a confidential database for later review
      by the principal investigator.

      Treatment allocation:

      All eligible patients (i.e., meeting inclusion criteria and no exclusion criteria) will be
      treated and observed per the research protocol. All patients will maintain the right to
      refuse participation and receive a specific treatment of the study if desired.

      Trial Population:

      The target sample size is 70 patients for both the treatment and control groups (140 total)
      with each group split evenly between males and females. There will be one actively enrolling
      surgeon (Dr. Brett Levine). The goal is to enroll a total of 140 subjects experiencing joint
      pain that warrants a Total knee arthroplasty (TKA). The specific diagnosis for the joint pain
      will not direct the subjects' assignment or eligibility at the time of surgery. All 140
      patients will be enrolled from the office of the primary investigator (Dr. Brett Levine). All
      indications for TKA will be included unless one of the exclusion criteria is met.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary--Percent Change of Pre- to Post-Operative Hemoglobin</measure>
    <time_frame>Pre-operative to 1 month</time_frame>
    <description>Pre-operative hemoglobin values from routine CBC no earlier than 1 month prior to surgery were compared to post-operative hemoglobin values from routine CBC after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Blood Loss</measure>
    <time_frame>Collected during surgery and in first 2-3 days after surgery</time_frame>
    <description>Combination of intraoperative and postoperative blood loss for participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Transfusions</measure>
    <time_frame>3 days</time_frame>
    <description>The number of transfusions each patient receives during their postoperative hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Blood Loss</measure>
    <time_frame>3 days</time_frame>
    <description>Measured as drainage output from postoperative drains during hospitalization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Intraoperative Bleeding</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group. Will not receive the fibrin spray.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group--Evicel Fibrin Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive the fibrin spray after implantation of device but before the wound is closed.
Patients will be randomized to receive spray or not and postop parameters measured.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evicel Fibrin Spray</intervention_name>
    <description>10cc syringe dose, once at the end of TKA</description>
    <arm_group_label>Treatment Group--Evicel Fibrin Spray</arm_group_label>
    <other_name>Produced by OMRIX Biopharmaceuticals, Ltd.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be male or female of any race

          -  Ages 18-80 years old

          -  Patients must be undergoing an elective, primary knee arthroplasty performed by the
             principal investigator

        Exclusion Criteria:

          -  Allergy or intolerance to the study materials

          -  Surgical intervention during the past month for the treatment of the painful joint or
             its underlying etiology

          -  History of previous surgeries on the affected joint including previous arthroscopy
             (open surgeries)

          -  Women that are pregnant or may become pregnant

          -  Patient declines to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brett R Levine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush Oak Park Hospital</name>
      <address>
        <city>Oak Park</city>
        <state>Illinois</state>
        <zip>60304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Levy O, Martinowitz U, Oran A, Tauber C, Horoszowski H. The use of fibrin tissue adhesive to reduce blood loss and the need for blood transfusion after total knee arthroplasty. A prospective, randomized, multicenter study. J Bone Joint Surg Am. 1999 Nov;81(11):1580-8.</citation>
    <PMID>10565650</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang GJ, Hungerford DS, Savory CG, Rosenberg AG, Mont MA, Burks SG, Mayers SL, Spotnitz WD. Use of fibrin sealant to reduce bloody drainage and hemoglobin loss after total knee arthroplasty: a brief note on a randomized prospective trial. J Bone Joint Surg Am. 2001 Oct;83-A(10):1503-5.</citation>
    <PMID>11679600</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2012</study_first_submitted>
  <study_first_submitted_qc>July 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2012</study_first_posted>
  <results_first_submitted>October 27, 2015</results_first_submitted>
  <results_first_submitted_qc>January 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2016</results_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Brett Levine, MD</investigator_full_name>
    <investigator_title>Assistant Professor and Associate Residency Director</investigator_title>
  </responsible_party>
  <keyword>Blood Loss</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Hematocrit</keyword>
  <keyword>Blood Transfusions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Prior to randomization, 21 patients were disqualified for protocol violation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>Control group. Will not receive the fibrin spray.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Group--Evicel Fibrin Spray</title>
          <description>Patient will receive the fibrin spray after implantation of device but before the wound is closed.
Patients will be randomized to receive spray or not and postop parameters measured.
Evicel Fibrin Spray: 10cc syringe dose, once at the end of TKA</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>Control group. Will not receive the fibrin spray.</description>
        </group>
        <group group_id="B2">
          <title>Treatment Group--Evicel Fibrin Spray</title>
          <description>Patient will receive the fibrin spray after implantation of device but before the wound is closed.
Patients will be randomized to receive spray or not and postop parameters measured.
Evicel Fibrin Spray: 10cc syringe dose, once at the end of TKA</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="9"/>
                    <measurement group_id="B2" value="64" spread="10"/>
                    <measurement group_id="B3" value="66" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary--Percent Change of Pre- to Post-Operative Hemoglobin</title>
        <description>Pre-operative hemoglobin values from routine CBC no earlier than 1 month prior to surgery were compared to post-operative hemoglobin values from routine CBC after surgery.</description>
        <time_frame>Pre-operative to 1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Control group. Will not receive the fibrin spray.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group--Evicel Fibrin Spray</title>
            <description>Patient will receive the fibrin spray after implantation of device but before the wound is closed.
Patients will be randomized to receive spray or not and postop parameters measured.
Evicel Fibrin Spray: 10cc syringe dose, once at the end of TKA</description>
          </group>
        </group_list>
        <measure>
          <title>Primary--Percent Change of Pre- to Post-Operative Hemoglobin</title>
          <description>Pre-operative hemoglobin values from routine CBC no earlier than 1 month prior to surgery were compared to post-operative hemoglobin values from routine CBC after surgery.</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="7.0"/>
                    <measurement group_id="O2" value="22.5" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Blood Loss</title>
        <description>Combination of intraoperative and postoperative blood loss for participants.</description>
        <time_frame>Collected during surgery and in first 2-3 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Control group. Will not receive the fibrin spray.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group--Evicel Fibrin Spray</title>
            <description>Patient will receive the fibrin spray after implantation of device but before the wound is closed.
Patients will be randomized to receive spray or not and postop parameters measured.
Evicel Fibrin Spray: 10cc syringe dose, once at the end of TKA</description>
          </group>
        </group_list>
        <measure>
          <title>Total Blood Loss</title>
          <description>Combination of intraoperative and postoperative blood loss for participants.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="605" spread="288"/>
                    <measurement group_id="O2" value="621" spread="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Transfusions</title>
        <description>The number of transfusions each patient receives during their postoperative hospitalization.</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Control group. Will not receive the fibrin spray.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group--Evicel Fibrin Spray</title>
            <description>Patient will receive the fibrin spray after implantation of device but before the wound is closed.
Patients will be randomized to receive spray or not and postop parameters measured.
Evicel Fibrin Spray: 10cc syringe dose, once at the end of TKA</description>
          </group>
        </group_list>
        <measure>
          <title>Total Transfusions</title>
          <description>The number of transfusions each patient receives during their postoperative hospitalization.</description>
          <units>Number of transfusions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Blood Loss</title>
        <description>Measured as drainage output from postoperative drains during hospitalization.</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Control group. Will not receive the fibrin spray.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group--Evicel Fibrin Spray</title>
            <description>Patient will receive the fibrin spray after implantation of device but before the wound is closed.
Patients will be randomized to receive spray or not and postop parameters measured.
Evicel Fibrin Spray: 10cc syringe dose, once at the end of TKA</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Blood Loss</title>
          <description>Measured as drainage output from postoperative drains during hospitalization.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="543" spread="273"/>
                    <measurement group_id="O2" value="555" spread="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>Control group. Will not receive the fibrin spray.</description>
        </group>
        <group group_id="E2">
          <title>Treatment Group--Evicel Fibrin Spray</title>
          <description>Patient will receive the fibrin spray after implantation of device but before the wound is closed.
Patients will be randomized to receive spray or not and postop parameters measured.
Evicel Fibrin Spray: 10cc syringe dose, once at the end of TKA</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Superficial Wound Dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sean Kearns</name_or_title>
      <organization>Rush University</organization>
      <phone>708-236-2664</phone>
      <email>sean_m_kearns@rush.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

